{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:11:34Z","timestamp":1770063094485,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2490-14-11","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T13:02:47Z","timestamp":1390827767000},"source":"Crossref","is-referenced-by-count":18,"title":["Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)"],"prefix":"10.1186","volume":"14","author":[{"given":"Naim B","family":"Farah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Amr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"issue":"2","key":"305_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2217\/1750743X.1.2.281","volume":"1","author":"TP Kresowik","year":"2009","unstructured":"Kresowik TP, Griffith TS: Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy. 2009, 1 (2): 281-288. 10.2217\/1750743X.1.2.281.","journal-title":"Immunotherapy"},{"key":"305_CR2","unstructured":"Fabian S, Rodrigo Q, de Medina SGD, Laurent S, Abbou CC, Chopin DK: Bacille Calmette-Guerin (BCG) for the treatment of superficial bladder cancer. a critical analysis of 25 years' experience with various therapeutic schedules.\n                    http:\/\/www.urofrance.org\/fileadmin\/medias\/sncuf\/lettre....\/25-ans-bcg.pdf\n                    \n                  ,"},{"issue":"6","key":"305_CR3","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG: Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer: a meta-analysis of randomize trials. Urology. 2006, 67 (6): 1216-1223. 10.1016\/j.urology.2005.12.014.","journal-title":"Urology"},{"key":"305_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"M Per-Uno","year":"2009","unstructured":"Per-Uno M, Per-Uno M, Sylvester RJ, Crawford DE, Martin F, Susanne K, Erkki R, Eduardo S, Di Stasi SM, Alfred Witjes J: An individual patient data meta-analysis of the long-term out cone of randomized studies comparing intravesical mitomycin C versus bacillus calmette-guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009, 56: 247-256. 10.1016\/j.eururo.2009.04.038.","journal-title":"Eur Urol"},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002, 168: 1964-1970. 10.1016\/S0022-5347(05)64273-5.","journal-title":"J Urol"},{"key":"305_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","volume":"153","author":"PDJ Vegt","year":"1995","unstructured":"Vegt PDJ, Alfred Witjes J, Witjes WPJ, Doesburg WH, Debruyne FMJ, van der Meijden APM: A randomize study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol. 1995, 153: 929-933. 10.1016\/S0022-5347(01)67606-7.","journal-title":"J Urol"},{"issue":"1 Suppl 1","key":"305_CR7","first-page":"10","volume":"14","author":"WP Witjes","year":"1996","unstructured":"Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ: Update on the Dutch cooperative trial: mitomycin versus bacillus Calmette-Guerin- Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTa-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch south east cooperative urological group. Semin Urol Oncol. 1996, 14 (1 Suppl 1): 10-16.","journal-title":"Semin Urol Oncol"},{"key":"305_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","volume":"75","author":"H Akaza","year":"1995","unstructured":"Akaza H, Hinotsu S, Aso Y, Kakizoe T, Bladder Cancer BCG, Group S: Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four year results. Cancer. 1995, 75: 552-559. 10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H.","journal-title":"Cancer"},{"key":"305_CR9","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Barton Grossman H, Beck TM, Liemert JT, David Crawford E: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional carcinoma of the bladder: a randomized southwest oncology group study. J Urol. 2000, 163: 1124-1129. 10.1016\/S0022-5347(05)67707-5.","journal-title":"J Urol"},{"issue":"Supplement 3","key":"305_CR10","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1086\/314064","volume":"31","author":"DL Lamm","year":"2000","unstructured":"Lamm DL: Efficacy and safety of bacillus Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000, 31 (Supplement 3): S86-S90. 10.1086\/314064. 10.1086\/314064","journal-title":"Clin Infect Dis"},{"key":"305_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.eursup.2006.04.008","volume":"5","author":"D Lamm","year":"2006","unstructured":"Lamm D: Improving patient outcomes: Optimal BCG treatment regimen to prevent progression in superficial bladder cancer. Eur Urol Suppl. 2006, 5: 654-659. 10.1016\/j.eursup.2006.04.008.","journal-title":"Eur Urol Suppl"},{"issue":"suppl 1","key":"305_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000052376","volume":"37","author":"DL Lamm","year":"2000","unstructured":"Lamm DL: Preventing progression and improving survival with BCG maintenance. Eur Urol. 2000, 37 (suppl 1): 9-15.","journal-title":"Eur Urol"},{"key":"305_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nrurol.2013.194","volume":"10","author":"G Christine","year":"2013","unstructured":"Christine G, Hugh M, Muhammad Shamim K, Lewis DJM: BCG immunotherapy for bladder cancer- the effect of sub-strain difference. Nat Rev Urol. 2013, 10: 580-588. 10.1038\/nrurol.2013.194. published on line 17 September 2013; doi:10.1038\/nrurol.2013.194","journal-title":"Nat Rev Urol"},{"key":"305_CR14","first-page":"13:00","volume-title":"Freitag","author":"JR Gsponer","year":"2012","unstructured":"Gsponer JR, Bornand D, Bachmann A, Albert ML, Thalmann GN, Rentsch CA: Intravesical treatment of non-muscle invasive bladder cancer: global distribution of BCG strains and potential health economic impact of strain differences - Switzerland as an example. Freitag. 2012, 13:00-13:05."},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","volume":"169","author":"HW Herr","year":"2003","unstructured":"Herr HW, Dalbagni G: Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003, 169: 1706-1708. 10.1097\/01.ju.0000062605.92268.c6. Pub-Med","journal-title":"J Urol"},{"key":"305_CR16","first-page":"525","volume-title":"The Urology Clinics of North America, Volume 18","author":"HW Herr","year":"1991","unstructured":"Herr HW: Transurethral resection and intravesical therapy of superficial bladder tumors. The Urology Clinics of North America, Volume 18. Edited by: Fair WR. 1991, Philadelphia: WB Saunders, 525-8."},{"key":"305_CR17","first-page":"1493","volume":"32","author":"C In-Chang","year":"2012","unstructured":"In-Chang C, Kim EKy, Jae Young J, Ho Kyung S, Jinsoo C, Weo Seo P, Kang Hyun L: Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea. Anticancer Res. 2012, 32: 1493-1498.","journal-title":"Anticancer Res"},{"issue":"2","key":"305_CR18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3892\/etm.2011.400","volume":"3","author":"Y Koo Han","year":"2012","unstructured":"Koo Han Y, Tea Joon L, Sung-Goo C: Monthly intravesical bacillus Calmette-Guerin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute. Exp Ther Med. 2012, 3 (2): 221-225.","journal-title":"Exp Ther Med"},{"key":"305_CR19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","volume":"52","author":"MG Friedrick","year":"2007","unstructured":"Friedrick MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compare with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007, 52: 1123-1130. 10.1016\/j.eururo.2007.02.063.","journal-title":"Eur Urol"},{"key":"305_CR20","doi-asserted-by":"publisher","first-page":"181987","DOI":"10.1155\/2012\/181987","volume":"2012","author":"EJ Askeland","year":"2012","unstructured":"Askeland EJ, Newton MR, O'Donnell MA, Yi L: Bladder cancer immunotherapy: BCG and beyond. Adv Urol. 2012, 2012: 181987-","journal-title":"Adv Urol"},{"key":"305_CR21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","volume":"5","author":"RA Badalament","year":"1987","unstructured":"Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF, Fair WR, Oettgen HF: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Onco. 1987, 5: 441-449.","journal-title":"J Clin Onco"},{"issue":"5","key":"305_CR22","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","volume":"165","author":"J Palou","year":"2001","unstructured":"Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vincente-Rodriguez J: Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and\/or high grade bladder tumors. J Urol. 2001, 165 (5): 1488-1491. 10.1016\/S0022-5347(05)66333-1.","journal-title":"J Urol"},{"issue":"10","key":"305_CR23","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1111\/j.1464-410X.2010.09923.x","volume":"107","author":"V Strock","year":"2011","unstructured":"Strock V, Dotevall L, Sandberg T, Gustafsson CK, Holmang S: Late bacille Calmette-Guerin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment. BJU Int. 2011, 107 (10): 1592-1597. 10.1111\/j.1464-410X.2010.09923.x.","journal-title":"BJU Int"},{"issue":"2","key":"305_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","volume":"71","author":"BL Gallagher","year":"2008","unstructured":"Gallagher BL, Joudi FN, Maymi JL, O'Donnell MA: Ipact of previous bacille Calmette-Guerin failure pattern in subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology. 2008, 71 (2): 297-301. 10.1016\/j.urology.2007.09.050.","journal-title":"Urology"},{"key":"305_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1464-410X.2007.06912.x","volume":"100","author":"EH Lambert","year":"2007","unstructured":"Lambert EH, Pierorazio PM, Olsson CA, Benson MC, MckKiernan JM, Poon S: The increase use of intravesical therapies for stag T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007, 100: 336-","journal-title":"BJU Int"},{"key":"305_CR26","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1097\/01.ju.0000066840.42991.4a","volume":"169","author":"P Michael","year":"2003","unstructured":"Michael P, Florent G, Delphine A-O, Djillali S, Bernard D, Marc Z: Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the urinary bladder: recurrence, progression and survival in a study of 57 patients. J Urol. 2003, 169: 2110-2212. 10.1097\/01.ju.0000066840.42991.4a.","journal-title":"J Urol"},{"issue":"4 Suppl","key":"305_CR27","first-page":"223","volume":"22","author":"V Pansadoro","year":"2003","unstructured":"Pansadoro V, Emiliozzi P, Depaula F, Scarpone P, Pizzo M, Federico G, Martini M, Pansadoro A, Stenberg CN: High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with bacillus Calmette-Guerin (BCG). J Exp Clin Cancer Res. 2003, 22 (4 Suppl): 223-227.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"305_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF00441115","volume":"14","author":"APMvd Mejiden","year":"1986","unstructured":"Mejiden APMvd, Steerenberg PA, de Jong WH, Bogman MJJ, Feitz WFJ, Hendriks BT, Debruyne FMJ, Ruitenberg EJ: The effect of intravesical and intra-dermal application of a new BCG on dog bladder. Urol Res. 1986, 14 (4): 207-210. 10.1007\/BF00441115.","journal-title":"Urol Res"},{"key":"305_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1475-2867-10-21","volume":"10","author":"S Katja","year":"2010","unstructured":"Katja S, Martin F, Thomas S, Inge-Marie H, Eberhard S: BCG strain S4-Jena: an early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis. Canc Cell Int. 2010, 10: 21-10.1186\/1475-2867-10-21.","journal-title":"Canc Cell Int"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-14-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2490-14-11\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-14-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-14-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T15:15:51Z","timestamp":1548083751000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/1471-2490-14-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/1471-2490-14-11","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,27]]},"article-number":"11"}}